



## Clinical trial results:

### A Phase IIIb, Open Label Extension Study Evaluating The Safety And Tolerability of AMX0035 Up To 108 Weeks In Adult Participants with Amyotrophic Lateral Sclerosis (ALS) Previously Enrolled In Study A35-004 (PHOENIX)

#### Summary

EudraCT number	2022-002348-33
Trial protocol	ES NL IT FR SE IE PL DE BE PT
Global end of trial date	30 October 2024

#### Results information

Result version number	v1 (current)
This version publication date	16 April 2026
First version publication date	16 April 2026

#### Trial information

##### Trial identification

Sponsor protocol code	A35-011
-----------------------	---------

##### Additional study identifiers

ISRCTN number	-
ClinicalTrials.gov id (NCT number)	NCT05619783
WHO universal trial number (UTN)	-

Notes:

#### Sponsors

Sponsor organisation name	Amylyx Pharmaceuticals, Inc.
Sponsor organisation address	55 Cambridge Parkway Suite 6W, Cambridge, United States, MA 02142
Public contact	Medical Information, Amylyx Pharmaceuticals EMEA B.V., +1 8773741208, clinicaltrials@amylyx.com
Scientific contact	Tammy Sarnelli, Amylyx Pharmaceuticals EMEA B.V., +1 857-320-6154, tammy_sarnelli@amylyx.com

Notes:

#### Paediatric regulatory details

Is trial part of an agreed paediatric investigation plan (PIP)	No
Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial?	No
Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial?	No

Notes:

## Results analysis stage

Analysis stage	Final
Date of interim/final analysis	05 November 2025
Is this the analysis of the primary completion data?	Yes
Primary completion date	30 October 2024
Global end of trial reached?	Yes
Global end of trial date	30 October 2024
Was the trial ended prematurely?	Yes

Notes:

## General information about the trial

Main objective of the trial:

To assess the long-term safety and tolerability of treatment with AMX0035

Protection of trial subjects:

The Phase 3b A35-011 (PHOENIX Open-Label Extension [OLE]) study was initiated with the prior written approval of properly constituted Independent Ethics Committees (IECs).

PHOENIX-OLE was conducted in compliance with the International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH) E6 (R2) GCP guideline; the ethical principles of the Declaration of Helsinki; and applicable local regulations.

The study was also performed in accordance with applicable local data privacy and security regulations.

Background therapy:

Not applicable.

Evidence for comparator:

Not applicable.

Actual start date of recruitment	02 January 2023
Long term follow-up planned	No
Independent data monitoring committee (IDMC) involvement?	No

Notes:

## Population of trial subjects

### Subjects enrolled per country

Country: Number of subjects enrolled	United Kingdom: 10
Country: Number of subjects enrolled	Netherlands: 21
Country: Number of subjects enrolled	Poland: 49
Country: Number of subjects enrolled	Portugal: 5
Country: Number of subjects enrolled	Spain: 64
Country: Number of subjects enrolled	Sweden: 14
Country: Number of subjects enrolled	Belgium: 6
Country: Number of subjects enrolled	France: 68
Country: Number of subjects enrolled	Germany: 26
Country: Number of subjects enrolled	Ireland: 8
Country: Number of subjects enrolled	Italy: 82
Worldwide total number of subjects	353
EEA total number of subjects	343

Notes:

<b>Subjects enrolled per age group</b>	
In utero	0
Preterm newborn - gestational age < 37 wk	0
Newborns (0-27 days)	0
Infants and toddlers (28 days-23 months)	0
Children (2-11 years)	0
Adolescents (12-17 years)	0
Adults (18-64 years)	240
From 65 to 84 years	113
85 years and over	0

## Subject disposition

### Recruitment

Recruitment details:

Up to 600 participants were planned to be enrolled in PHOENIX-OLE.

A total of 352 participants were ultimately enrolled and treated before the early termination of the study by the Sponsor as described above.

### Pre-assignment

Screening details:

A total of 354 prospective participants were screened for the PHOENIX-OLE study, of whom 352 were ultimately both enrolled and treated. One participant was randomized, enrolled, and assigned to, but did not actually receive study treatment.

### Period 1

Period 1 title	Treatment period (overall period)
Is this the baseline period?	Yes
Allocation method	Not applicable
Blinding used	Not blinded

### Arms

Arm title	AMX0035
-----------	---------

Arm description:

AMX0035, supplied as a powder-filled sachet containing 3 g sodium phenylbutyrate (PB), 1 g taurursodiol/ursodoxicoltaurine (TURSO), and excipients, administered orally.

Arm type	Experimental
Investigational medicinal product name	AMX0035
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Powder for oral suspension in sachet, Powder for oral solution in sachet
Routes of administration	Oral use

Dosage and administration details:

Two (2) AMX0035 sachets daily (one morning dose and one evening dose), starting on Day 1 and continuing for the duration of the study.

If twice-daily dosing was poorly tolerated, dosing interruptions and dose reductions (i.e., to one sachet per day) were permitted per protocol.

Number of subjects in period 1	AMX0035
Started	353
Completed	0
Not completed	353
Withdrawal of Consent	55
Death	88
Study Terminated by Sponsor	206
Lost to follow-up	4



## Baseline characteristics

### Reporting groups

Reporting group title	AMX0035
-----------------------	---------

Reporting group description:

AMX0035, supplied as a powder-filled sachet containing 3 g sodium phenylbutyrate (PB), 1 g taurursodiol/ursodoxicoltaurine (TURSO), and excipients, administered orally.

Reporting group values	AMX0035	Total	
Number of subjects	353	353	
Age categorical			
Units: Subjects			
Adults (18-64 years)	240	240	
From 65-84 years	113	113	
Age continuous			
Units: years			
median	60.0		
full range (min-max)	21 to 84	-	
Gender categorical			
Units: Subjects			
Female	131	131	
Male	222	222	

## End points

### End points reporting groups

Reporting group title	AMX0035
Reporting group description: AMX0035, supplied as a powder-filled sachet containing 3 g sodium phenylbutyrate (PB), 1 g taurursodiol/ursodoxicoltaurine (TURSO), and excipients, administered orally.	

### Primary: Incidence of all AEs, AEs leading to treatment discontinuation or study withdrawal, and all serious adverse events (SAEs) in participants treated with AMX0035

End point title	Incidence of all AEs, AEs leading to treatment discontinuation or study withdrawal, and all serious adverse events (SAEs) in participants treated with AMX0035 <sup>[1]</sup>
End point description: Incidence of all AEs, AEs leading to treatment discontinuation or study withdrawal, and all serious adverse events (SAEs) in participants treated with AMX0035.	
End point type	Primary
End point timeframe: 108 weeks	

Notes:

[1] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: Only descriptive analyses were performed for the primary safety endpoint.

End point values	AMX0035			
Subject group type	Reporting group			
Number of subjects analysed	352			
Units: participants				
Any TEAE - Number of Participants	266			
Any TEAE - Number of AEs	817			
Any Drug-Related TEAE - Number of Participants	86			
Any Drug-Related TEAE - Number of AEs	158			
Any Serious TEAE - Number of Participants	117			
Any Serious TEAE - Number of AEs	181			
Any Drug-Related Serious TEAE - Number of Particip	4			
Any Drug-Related Serious TEAE - Number of AEs	4			
Any Severe TEAE - Number of Participants	100			
Any Severe TEAE - Number of AEs	139			
Any Drug-Related Severe - Number of Partic TEAE -	3			
Any Drug-Related Severe TEAE - Number of AEs	3			
Any Fatal TEAE - Number of Participants	72			
Any Fatal TEAE - Number of AEs	90			
Any Drug-Related Fatal TEAE - Number of Participan	0			

Any Drug-Related Fatal TEAE - Number of AEs	0			
Any TEAE Leading to Dose Change - Number of Partic	106			
Any TEAE Leading to Dose Change - Number of AEs	189			
Any TEAE Leading to Dose Reduction - Number of Par	22			
Any TEAE Leading to Dose Reduction - Number of AEs	33			
Any TEAE Leading to Dose Interruption - Num of pts	30			
Any TEAE Leading to Dose Interruption - Num of AEs	58			
Any TEAE Leading to Drug Withdrawal - Num of pts	73			
Any TEAE Leading to Drug Withdrawal - Num of AEs	97			

### Statistical analyses

No statistical analyses for this end point



## Adverse events

### Adverse events information

Timeframe for reporting adverse events:

PHOENIX-OLE was terminated early by the Sponsor after the parent PHOENIX trial did not show clinical benefit in its primary efficacy outcome. Data collection in PHOENIX-OLE therefore did not encompass the 108 weeks of study treatment planned per protocol.

Adverse event reporting additional description:

A total of 266 participants experienced at least one TEAE during their PHOENIX-OLE participation, with a total of 817 TEAEs reported. A total of 117 participants experienced at least one treatment-emergent SAE, and 72 participants died due to one or more such events.

Assessment type	Systematic
-----------------	------------

### Dictionary used

Dictionary name	MedDRA
Dictionary version	25.1

### Reporting groups

Reporting group title	AMX0035
-----------------------	---------

Reporting group description: -

Serious adverse events	AMX0035		
Total subjects affected by serious adverse events			
subjects affected / exposed	117 / 352 (33.24%)		
number of deaths (all causes)	72		
number of deaths resulting from adverse events	72		
Vascular disorders			
Circulatory collapse			
subjects affected / exposed	1 / 352 (0.28%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 1		
Surgical and medical procedures			
Euthanasia			
subjects affected / exposed	1 / 352 (0.28%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 1		
Gastrostomy			
subjects affected / exposed	1 / 352 (0.28%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
General disorders and administration site conditions			

Death			
subjects affected / exposed	4 / 352 (1.14%)		
occurrences causally related to treatment / all	0 / 4		
deaths causally related to treatment / all	0 / 4		
Disease progression			
subjects affected / exposed	3 / 352 (0.85%)		
occurrences causally related to treatment / all	0 / 3		
deaths causally related to treatment / all	0 / 3		
Chest pain			
subjects affected / exposed	1 / 352 (0.28%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Complication associated with device			
subjects affected / exposed	1 / 352 (0.28%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Pain			
subjects affected / exposed	1 / 352 (0.28%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Pyrexia			
subjects affected / exposed	1 / 352 (0.28%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Respiratory, thoracic and mediastinal disorders			
Respiratory failure			
subjects affected / exposed	41 / 352 (11.65%)		
occurrences causally related to treatment / all	1 / 41		
deaths causally related to treatment / all	0 / 28		
Acute respiratory failure			
subjects affected / exposed	11 / 352 (3.13%)		
occurrences causally related to treatment / all	0 / 11		
deaths causally related to treatment / all	0 / 9		

Dyspnoea				
subjects affected / exposed	8 / 352 (2.27%)			
occurrences causally related to treatment / all	0 / 8			
deaths causally related to treatment / all	0 / 5			
Respiratory arrest				
subjects affected / exposed	2 / 352 (0.57%)			
occurrences causally related to treatment / all	0 / 2			
deaths causally related to treatment / all	0 / 2			
Aspiration				
subjects affected / exposed	2 / 352 (0.57%)			
occurrences causally related to treatment / all	0 / 2			
deaths causally related to treatment / all	0 / 1			
Atelectasis				
subjects affected / exposed	1 / 352 (0.28%)			
occurrences causally related to treatment / all	0 / 1			
deaths causally related to treatment / all	0 / 1			
Choking				
subjects affected / exposed	1 / 352 (0.28%)			
occurrences causally related to treatment / all	0 / 1			
deaths causally related to treatment / all	0 / 1			
Diaphragm muscle weakness				
subjects affected / exposed	2 / 352 (0.57%)			
occurrences causally related to treatment / all	0 / 2			
deaths causally related to treatment / all	0 / 1			
Hypoxia				
subjects affected / exposed	1 / 352 (0.28%)			
occurrences causally related to treatment / all	0 / 1			
deaths causally related to treatment / all	0 / 1			
Lung disorder				
subjects affected / exposed	3 / 352 (0.85%)			
occurrences causally related to treatment / all	0 / 3			
deaths causally related to treatment / all	0 / 1			
Obstructive airways disorder				

subjects affected / exposed	1 / 352 (0.28%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 1		
Respiratory distress			
subjects affected / exposed	1 / 352 (0.28%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 1		
Upper airway obstruction			
subjects affected / exposed	1 / 352 (0.28%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 1		
Pulmonary embolism			
subjects affected / exposed	2 / 352 (0.57%)		
occurrences causally related to treatment / all	0 / 2		
deaths causally related to treatment / all	0 / 0		
Hypoventilation			
subjects affected / exposed	1 / 352 (0.28%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Upper-airway cough syndrome			
subjects affected / exposed	1 / 352 (0.28%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Psychiatric disorders			
Completed suicide			
subjects affected / exposed	1 / 352 (0.28%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 1		
Anxiety			
subjects affected / exposed	1 / 352 (0.28%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Sleep disorder			

subjects affected / exposed	1 / 352 (0.28%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Investigations			
Oxygen saturation decreased			
subjects affected / exposed	1 / 352 (0.28%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Injury, poisoning and procedural complications			
Femur fracture			
subjects affected / exposed	1 / 352 (0.28%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Head injury			
subjects affected / exposed	1 / 352 (0.28%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Jaw fracture			
subjects affected / exposed	1 / 352 (0.28%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Ligament injury			
subjects affected / exposed	1 / 352 (0.28%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Cardiac disorders			
Cardio-respiratory arrest			
subjects affected / exposed	4 / 352 (1.14%)		
occurrences causally related to treatment / all	0 / 4		
deaths causally related to treatment / all	0 / 4		
Acute myocardial infarction			
subjects affected / exposed	1 / 352 (0.28%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		

Myocardial infarction			
subjects affected / exposed	1 / 352 (0.28%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Nervous system disorders			
Haemorrhagic stroke			
subjects affected / exposed	1 / 352 (0.28%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 1		
Muscle spasticity			
subjects affected / exposed	1 / 352 (0.28%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Seizure			
subjects affected / exposed	1 / 352 (0.28%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Subarachnoid haemorrhage			
subjects affected / exposed	1 / 352 (0.28%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Transient ischaemic attack			
subjects affected / exposed	1 / 352 (0.28%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Blood and lymphatic system disorders			
Agranulocytosis			
subjects affected / exposed	1 / 352 (0.28%)		
occurrences causally related to treatment / all	1 / 1		
deaths causally related to treatment / all	0 / 0		
Gastrointestinal disorders			
Constipation			

subjects affected / exposed	1 / 352 (0.28%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 1		
Diarrhoea			
subjects affected / exposed	1 / 352 (0.28%)		
occurrences causally related to treatment / all	1 / 1		
deaths causally related to treatment / all	0 / 0		
Pancreatitis			
subjects affected / exposed	1 / 352 (0.28%)		
occurrences causally related to treatment / all	1 / 1		
deaths causally related to treatment / all	0 / 0		
Dysphagia			
subjects affected / exposed	2 / 352 (0.57%)		
occurrences causally related to treatment / all	0 / 2		
deaths causally related to treatment / all	0 / 0		
Faecaloma			
subjects affected / exposed	1 / 352 (0.28%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Gastric prolapse			
subjects affected / exposed	1 / 352 (0.28%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Gastric ulcer			
subjects affected / exposed	1 / 352 (0.28%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Salivary hypersecretion			
subjects affected / exposed	1 / 352 (0.28%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Hepatobiliary disorders			
Hepatic cirrhosis			

subjects affected / exposed	1 / 352 (0.28%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 1		
Renal and urinary disorders			
Urinary retention			
subjects affected / exposed	1 / 352 (0.28%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Infections and infestations			
Pneumonia			
subjects affected / exposed	19 / 352 (5.40%)		
occurrences causally related to treatment / all	0 / 19		
deaths causally related to treatment / all	0 / 5		
Pneumonia aspiration			
subjects affected / exposed	7 / 352 (1.99%)		
occurrences causally related to treatment / all	0 / 7		
deaths causally related to treatment / all	0 / 4		
Respiratory tract infection			
subjects affected / exposed	5 / 352 (1.42%)		
occurrences causally related to treatment / all	0 / 5		
deaths causally related to treatment / all	0 / 3		
Bronchitis			
subjects affected / exposed	4 / 352 (1.14%)		
occurrences causally related to treatment / all	0 / 4		
deaths causally related to treatment / all	0 / 1		
COVID-19			
subjects affected / exposed	3 / 352 (0.85%)		
occurrences causally related to treatment / all	0 / 3		
deaths causally related to treatment / all	0 / 1		
Cardiac arrest			
subjects affected / exposed	1 / 352 (0.28%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 1		
Cardiac failure			



subjects affected / exposed	1 / 352 (0.28%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 1		
Cardiopulmonary failure			
subjects affected / exposed	1 / 352 (0.28%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 1		
Cellulitis			
subjects affected / exposed	1 / 352 (0.28%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Clostridium difficile infection			
subjects affected / exposed	1 / 352 (0.28%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Infection			
subjects affected / exposed	1 / 352 (0.28%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Upper respiratory tract infection			
subjects affected / exposed	1 / 352 (0.28%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Urinary tract infection			
subjects affected / exposed	1 / 352 (0.28%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		

Frequency threshold for reporting non-serious adverse events: 2 %

<b>Non-serious adverse events</b>	AMX0035		
Total subjects affected by non-serious adverse events			
subjects affected / exposed	64 / 352 (18.18%)		
Nervous system disorders			
Dizziness			
subjects affected / exposed	7 / 352 (1.99%)		
occurrences (all)	7		
Gastrointestinal disorders			
Diarrhoea			
subjects affected / exposed	37 / 352 (10.51%)		
occurrences (all)	37		
Nausea			
subjects affected / exposed	14 / 352 (3.98%)		
occurrences (all)	14		
Abdominal pain			
subjects affected / exposed	6 / 352 (1.70%)		
occurrences (all)	6		

## More information

### Substantial protocol amendments (globally)

Were there any global substantial amendments to the protocol? No

---

### Interruptions (globally)

Were there any global interruptions to the trial? No

### Limitations and caveats

Limitations of the trial such as small numbers of subjects analysed or technical problems leading to unreliable data.

None
------

Notes: